Searched over 200M research papers for "mat treatment"
10 papers analyzed
Some studies suggest that medication-assisted treatment (MAT) improves substance use treatment engagement and reduces opioid use and mortality rates, while other studies indicate that meniscal allograft transplantation (MAT) can alleviate knee pain and improve function, and primary manual aspiration thrombectomy (MAT) is effective for acute ischemic stroke.
20 papers analyzed
Medication-Assisted Treatment (MAT) is a comprehensive approach combining medications with counseling and behavioral therapies to treat opioid use disorder (OUD). MAT has been shown to be effective in various settings, including prisons, jails, and community healthcare environments. This article synthesizes recent research on the effectiveness of MAT, particularly focusing on its impact on treatment engagement, opioid use reduction, recidivism, and mortality rates.
Studies have demonstrated that MAT, particularly methadone, when administered in correctional settings, significantly increases community substance use treatment engagement post-release. Data from randomized controlled trials (RCTs) involving 807 inmates showed that methadone provided during incarceration increased community treatment engagement (OR = 8.69) and reduced illicit opioid use (OR = 0.22) and injection drug use (OR = 0.26). However, methadone did not significantly reduce recidivism rates (OR = 0.93). Observational studies corroborate these findings, indicating consistent benefits of methadone in reducing opioid use post-release.
A systematic review and meta-analysis of 30 cohort studies involving 370,611 participants assessed the impact of MAT on mortality among individuals with OUD. The analysis revealed that the all-cause crude mortality rates (CMRs) were significantly lower for individuals receiving MAT (0.92 per 100 person-years) compared to those who were untreated (4.89 per 100 person-years). Similarly, overdose CMRs were lower during MAT (0.24 per 100 person-years) compared to the untreated period (2.43 per 100 person-years). The study also highlighted that retention in MAT for over one year was associated with a lower mortality rate compared to retention for one year or less.
The effectiveness of different MAT medications, including methadone, buprenorphine, and naltrexone, has been evaluated. Methadone and buprenorphine have shown similar efficacy in reducing opioid use and improving treatment retention . Long-acting naltrexone has also demonstrated a positive impact on preventing premature death among individuals with OUD, with lower all-cause CMRs during treatment (0.26 per 100 person-years) compared to post-treatment periods.
While MAT offers significant benefits, its implementation in criminal justice settings poses ethical challenges. Ensuring voluntary participation and protecting individual autonomy within the complex environment of prisons and drug courts is crucial. Rigorous consent processes, akin to those in medical or sociobehavioral research, are recommended to safeguard the rights of individuals undergoing MAT.
MAT is a highly effective treatment for opioid use disorder, particularly in reducing opioid use, increasing treatment engagement, and lowering mortality rates. Methadone, buprenorphine, and naltrexone each offer unique benefits, with methadone showing significant efficacy in correctional settings and long-acting naltrexone demonstrating advantages in mortality prevention. However, ethical considerations in the implementation of MAT, especially in criminal justice settings, must be addressed to ensure voluntary participation and protect individual autonomy. Continued research and improved adherence to MAT protocols are essential for optimizing outcomes and reducing the burden of opioid use disorder.
Most relevant research papers on this topic